- Tous > Medicine Access and Rational Use > Better Medicines for Children
- Tous > Quality and Safety: Medicines > Quality Assurance
- Mots-clés > compounding / manipulation of a dosage form
- Mots-clés > Good Dispensing Practices
- Mots-clés > Good Manufacturing Practices (GMP)
- Mots-clés > medicines for children - formulations and adequate dosages
- Mots-clés > paediatric / child dosage form
- Mots-clés > pharmaceutical alternatives
- Mots-clés > pharmaceutical preparations - standards
- Mots-clés > standards of professional practice
(2016; 24 pages)
Paediatric patients should have access to authorized, age-appropriate preparations of medicines that can be administered safely and effectively. Nothing in this document should detract from this objective. However, it is recognized that such preparations are not always available and in such cases a safe and effective alternative must be sought.
In the context of paediatric pharmacy practice, and for the purpose of this document, compounding is the technique applied by pharmacists to produce medicines from active pharmaceutical ingredients (APIs) or using authorized medicines when no commercially available, authorized, age-appropriate or adequate dosage form exists.
The risks and benefits of compounding and of the alternatives should be fully understood by practitioners. Practitioners who do not have appropriate knowledge should seek advice.
Compared to the use of authorized medicines there are significant risks associated with compounding; quality, safety and efficacy can rarely all be assured, and many errors have been reported in the preparation of such medicines. In some situations compounding of a medicine for a child may be the only option, which may be supported by evidence of quality and occasionally evidence of bioavailability by industry or other parties, such as academia. There may be alternatives to compounding, which should also be considered, for example, use of a commercially available therapeutic alternative or manipulation of authorized dosage forms.
This points-to-consider document is supported by a literature review of the evidence available. An annex to the report contains an update on the abstracts and papers published in 2010–2015.
The document addresses mainly paediatric medicines for oral administration.